Medtronic to separate diabetes business following recent struggles

Go back to Medtronic to separate diabetes business following recent struggles

Evercore ISI Removes Medtronic, Inc. (MDT) from TAP List

May 21, 2025 4:52 PM EDT

Evercore ISI analyst Vijay Kumar reiterated an Outperform rating and $103.00 price target on Medtronic, Inc. (NYSE: MDT).

The analyst comments "Heading into earnings, we had TAP (tactical, actionable, positioning) calls on A, DHR, ENOV, MDT, SYK, TMO, & RVTY (previous tap note... More

Medtronic, Inc. (MDT) PT Lowered to $98 at Citi

May 21, 2025 2:08 PM EDT

Citi analyst Joanna Wuensch lowered the price target on Medtronic, Inc. (NYSE: MDT) to $98.00 (from $103.00) while maintaining a Buy rating.

The analyst comments "This was a quarterly report where many things seemed to go right for Medtronic: 1) FY4Q25 revenue $8.93B (up 5.4% y/y... More